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• The preferred therapy
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Castleman disease (CD) includes a group of rare and heterogeneous disorders with
characteristic lymph node histopathological abnormalities. CD can occur in a single lymph
node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric
lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes
human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-82
/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently
developed for iMCD by an international expert consortium convened by the Castleman
Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines
for the management of UCD. To this purpose, an international working group of 42 experts
from 10 countries was convened to establish consensus recommendations based on review of
treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion.
Complete surgical resection is often curative and is therefore the preferred first-line therapy, if
possible. The management of unresectable UCD is more challenging. Existing evidence
supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6
monoclonal antibody siltuximab should be considered for unresectable UCD patients with an
inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of
vital neighboring structures may be rendered amenable to resection by medical therapy (eg,
rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients
with persisting constitutional symptoms despite complete excision and normal laboratory
markers. We hope that these guidelines will improve outcomes in UCD and help treating
physicians decide the best therapeutic approach for their patients.
Submitted 3 September 2020; accepted 9 October 2020; published online 7
December 2020. DOI 10.1182/bloodadvances.2020003334.
Requests for data sharing should be e-mailed to the corresponding author.
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
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Introduction
Castleman disease (CD) comprises a heterogeneous group of
disorders involving a broad lymph node histopathological spectrum
and is classified as unicentric (UCD) or multicentric CD (MCD).
Classically, MCD presents with lymphadenopathy affecting multiple
lymph node stations and is associated with systemic symptoms,
such as fever, weight loss, and fatigue, driven by interleukin-6 (IL-6)
and other cytokines. MCD has been subclassified into human
herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated
MCD, and HHV-82/idiopathic MCD (iMCD).
UCD, which involves a single enlarged lymph node or multiple
enlarged lymph nodes within a single lymph node station, was first
described by Castleman and Towne1 in a patient with a mediastinal
mass in 1954 and soon thereafter by Castleman et al2 in a series of
12 cases in 1956. The disease typically behaves in an indolent
fashion, and enlargement of lymph nodes is gradual. Patients can be
diagnosed at any age (range, 2-84 years), with a median age of
diagnosis of 34 years and possibly a mild preponderance of female
patients.3 There are no known epidemiological factors that
predispose to the development of UCD. The incidence of UCD
has been estimated at 16 to 19 per million in the US population,
which translates to 5000 to 6000 patients per year.4 UCD is
virtually always HHV-82, but rare positive cases have been
reported, and these should be categorized and managed as
localized HHV-8–associated CD.5-8 Frequently, the diagnosis of UCD
is incidental, and the lymphadenopathy is often asymptomatic.
However, some patients present with symptoms resulting from
compression of vital structures (eg, airways, neurovascular bundles,
or ureters), whereas others will experience iMCD-like inflammatory
syndromes. In a large series of UCD cases, the most common sites of
involvement were the mediastinum (29%), neck (23%), abdomen
(21%), and retroperitoneum (17%).5 UCD can also occur in the axilla
and inguinal regions aswell as orbits, nasopharynx, and small bowel.9-12
Histopathological features of lymph nodes in UCD range from what
is considered to be hyaline vascular (HV) histopathology to
plasmacytic (PC) histopathology, with a mixed subgroup in between
that exhibits both features. HV histopathological features are most
often described in UCD, and these patients do not typically have
constitutional symptomatology or excess cytokine secretion.13-16
The lymph nodes show follicular hyperplasia with abnormal atretic
germinal centers, increased vascularity with hyalinization, prominent
and/or dysplastic follicular dendritic cells (FDCs), and expanded
mantle zones in an onion-skin appearance. Often there are radially
penetrating blood vessels causing a lollipop appearance, multiple
germinal centers within the same mantle zone referred to as
twinning or budding, tight aggregates of plasmacytoid dendritic
cells, and architectural disruption with obliterated sinuses. No
interfollicular plasmacytosis is present in HV UCD. An estimated
10% to 20% of UCD cases are considered to have PC
histopathology, involving variably sized germinal centers, inter-
follicular plasmacytosis, and occasionally systemic inflammatory
symptoms. Patients with PC UCD or mixed UCD often demonstrate
iMCD-like symptoms, such as night sweats, fever, anorexia, or weight
loss, as well as abnormal laboratory markers, such as anemia,
elevated erythrocyte sedimentation rate (ESR) or C-reactive protein
(CRP), hypoalbuminemia, or hypergammaglobulinemia.13,15-19 Oc-
casionally, AA amyloidosis as well as non–amyloidosis-related renal
disease can occur with UCD, mainly in the PC subtype.20-23 Life
expectancy is usually not changed after the diagnosis of UCD.
However, patients with UCD are at increased risk of developing
paraneoplastic pemphigus (PNP), bronchiolitis obliterans (BO),
AA amyloidosis, vascular neoplasms (eg, FDC sarcoma [FDCS]),
and possibly lymphomas.23-26
The pathogenesis of UCD is not well understood, but recent
evidence suggests that it may be caused in some patients by
a clonal expansion of lymph node stromal cells, including FDCs.27
FDCs are located in the germinal center of secondary follicles and
interact with B cells during germinal center reaction through antigen
presentation as well as chemokine and cytokine secretion. The
atrophic B cell–depleted germinal centers in UCD may reflect FDC
dysfunction.27-29 Recently, whole-exome sequencing revealed gain-
of-function somatic mutations in the kinase domain of the PDGFRB
gene in 7 of 41 UCD patients with HV histopathology; the mutations
were localized to CD452 cells, likely representing stromal cells.30
No clear associations have been made between UCD and active
viral infections, such as HIV or HHV-8.31 Further research is under
way to investigate the etiology and pathogenesis of UCD.
The Castleman Disease Collaborative Network (CDCN) has
established international consensus treatment guidelines for the
treatment of iMCD. Herein, we report our recommendations for the
management of UCD.
Methods
In 2016, the CDCN embarked on the establishment of treatment
guidelines for UCD and iMCD based on expert opinion and
review of the available literature by the Patient Care and Therapy
subcommittee of its scientific advisory board. This international
group of 42 participants from the United States, Japan, Hong
Kong, France, the United Kingdom, Germany, Italy, Norway, and
New Zealand comprises experts in hematology/oncology,
hematology, hematopathology, infectious diseases, immunol-
ogy, and surgery, as well as an iMCD patient. The working group
first met in December 2016 in San Diego, California, with
a follow-up meeting in December 2017 in Atlanta, Georgia, both
during America Society of Hematology annual conferences.
Three additional Web-based teleconferences were held in
August 2017, November 2017, and March 2018. The iMCD
guidelines were first published in 2018. Further discussion and
refinement of the UCD guidelines occurred from 2018 to 2020.
All relevant English-language literature was identified through
PubMed using the search term unicentric Castleman disease.
Included were case series and retrospective cohort studies
involving $5 patients in which treatments and responses were
reported and a clear distinction between UCD and MCD was
apparent. Literature from before 2012 was captured in the large
review by Talat et al.5 Systematic literature reviews after 2012
were excluded out of concern of possible overreporting on the
same patients. Articles primarily focusing on treatment of UCD
complications, such as PNP or BO, were also excluded. Table 1
summarizes published data and data from the ongoing ACCEL-
ERATE natural history registry32 from the CDCN and University
of Pennsylvania.12,19,33-45 The consensus focused on 2 main
topics: treatment of resectable UCD and treatment of unresect-
able UCD. Levels of evidence were modeled after National
Comprehensive Cancer Network guidelines.46
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Results
Diagnosis and evaluation of UCD
UCD is diagnosed after a lymph node biopsy to investigate solitary
lymphadenopathy, usually on clinical suspicion of lymphoma. Figure 1
displays the spectrum of changes seen in UCD, and Figure 2
provides representative images.
In addition to identifying histopathological features consistent with
UCD, a thorough workup for conditions with overlapping histopathol-
ogy is required (Table 2). It is important that a complete excisional
lymph node biopsy be performed rather than a fine-needle aspirate or
core biopsy. Unlike MCD with its many overlapping conditions, few
diseases other than UCD and lymphomas present with a solitary
enlarged lymph node with CD-like histopathology. Thymomas,
progressive transformation of germinal centers, unusual morpho-
logical variants of follicular lymphoma (FL), and lymphoproliferations
with regressive germinal centers, such as angioimmunoblastic T-cell
lymphoma, can sometimes show histopathological features reminis-
cent of HV UCD. PC UCD–like histopathological features may be
seen in many other conditions, such as infections, autoimmune
diseases, primary or acquired immunodeficiencies, such as advanced
phases of HIV-related lymphadenopathy, and malignancies, including
Hodgkin lymphoma, but the lymphadenopathy is usually not
unicentric.2,47-49
A series of laboratory and radiological investigations should be
performed (Table 3). First, computed tomography (CT) of the
neck, chest, abdomen, and pelvis is recommended to establish
the number of lymph node stations involved and differentiate UCD
from MCD. UCD should be suspected in the setting of a single
persistently enlarged lymph node or multiple enlarged lymph
nodes within a single lymph node station associated with moderate
to intense postcontrast enhancement on CT. UCD can present in
any lymph node in the body, and the size of the enlarged lymph is
often more bulky than the enlarged lymph nodes seen in MCD. If.1
lymph node is enlarged, those lymph nodes, by definition, must be
confined to a single lymph node region to be considered to
represent UCD.
CT–positron emission tomography scanning may provide additional
information regarding the metabolic activity of the affected lymph
nodes.50 High specific uptake values should raise the suspicion of
lymphoma, which is an important differential diagnosis. If suspected,
immunostaining for markers of lymphoma and clonality testing
should also be performed. Immunostaining for HHV-8 should also
be performed to identify rare cases of HHV-81 UCD. Clinical
evaluation includes assessment for constitutional symptoms (night
sweats, fever .38°C, weight loss, fatigue) and features such as
fluid accumulation (peripheral edema, pleural effusion, ascites).
Recommended laboratory testing comprises screening for anemia,
elevated CRP and/or ESR, hypoalbuminemia, hypergammaglobuline-
mia, and other markers of a cytokine-induced inflammatory response. It
should be noted that most cases of UCD are asymptomatic, and
often no laboratory abnormalities are present. HIV serology is
typically negative. As clinically indicated, further workup may
require assessment for PNP, BO, and POEMS syndrome. Rare
cases of UCD have light chain restriction of plasma cells, which
should prompt a workup for a clonal plasma cell dyscrasia with
associated POEMS syndrome.
Management of UCD
Important considerations in the management of UCD are: the
location of the enlarged lymph node, the resectability of the
enlarged lymph node, and the degree to which the enlarged lymph
node causes symptoms by compressing neighboring anatomy or
inducing a systemic inflammatory syndrome. Further consideration
should also be given to cases that are currently asymptomatic but
likely to become symptomatic through compression of neighboring
structures if the mass continues to grow. Resectability is a sub-
jective decision that should weigh the risks and benefits of surgery
and be made in consultation between the surgeon, clinician, and
patient. Multidisciplinary review is encouraged and should include
surgical specialists, radiologists, pathologists, and oncologists to
discuss treatment options to optimize patient outcomes.
Resectable UCD. We recommend that all patients first be
evaluated to determine whether the mass is amenable to complete
surgical extirpation (Figure 3). Complete surgical excision will
usually eliminate any systemic symptomatology and laboratory
abnormalities, if present. A review of the literature and real-world
data from the ACCELERATE study found a high response rate to
surgical excision (Table 1). In their first descriptions, Castleman
et al1,2 reported that surgery was an effective treatment modality,





Ongoing CD natural history study,
n (%)†
Surgical resection‡ 457 39
Evaluable 237 37
Response§ 228 (96.2) 31 (83.8)











Response§ 2 (50.0) 6 (75.0)




Response§ 8 (100) 1 (100)
Nonresponse‖ 0 0
Nonevaluable 7 0
*See supplemental Table 1.
†Includes patients enrolled by CD-treating physicians at experienced centers in Europe
or patients who self-enrolled and whose cases were reviewed by a panel of CD-treating
clinicians and pathologists.
‡Includes complete or partial resection of lymph node.
§Achieving at least 50% improvement of associated symptoms and at least 50%
reduction of mass.
‖Achieving ,50% improvement of associated symptoms or ,50% reduction of mass.
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and several early series confirmed that resection is the preferred
method of first-line treatment.15,16,48,51-53 Dispenzieri et al34
reported a 5-year overall survival (OS) of 91% in a series of 53
patients surgically treated at the Mayo Clinic and University of
Nebraska. Talat et al5 reported a similar OS of .90% in
a retrospective literature study comprising 278 UCD patients
treated with surgery, with a follow-up of up to 10 years. In the
Talat et al series, outcome was better when surgery was
performed for peripheral lymphadenopathy rather than central
lymphadenopathy located in the chest, abdomen, or pelvis. Death
resulting from disease occurred in only 1 (1.5%) of 68 patients
with peripheral lymphadenopathy vs 9 (6.1%) of 148 patients
with central lymphadenopathy (P , .05), presumably because
resection was virtually always feasible in those with peripheral
lymphadenopathy. Inability to resect the involved lymph node
proved the only factor predictive of a fatal outcome. In the
absence of persistent systemic symptoms or concern for
neighboring anatomic structures, residual small satellite lymph
nodes after resection can be observed, with spontaneous
involution often seen, after resection of the principal enlarged
lymph node.54 Symptoms resulting from AA amyloidosis as well
as non–amyloidosis-related renal disease typically improve over
the ensuing years after removal of unicentric disease.20-22
UCD should be managed in the first-line setting with surgery in both
children and adults. Parez et al55 reported 72 pediatric cases who
fared well with surgery (n 5 70) or radiotherapy (n 5 2). Taken
together, these and other reports provide level 2A evidence
establishing surgical resection as the treatment of choice for
UCD.19,37,45,56-59 Surgical resection is the most appropriate















































Figure 1. Spectrum of histopathological changes
seen in UCD. HV histopathological subtype is charac-
terized by the presence of regressed germinal centers
(GCs) and FDC prominence, whereas the plasmacytic
subtype exhibits hyperplastic GCs and profuse plas-
macytosis. Mixed subtype exhibits a combination of
HV and plasmacytic features. Lymph node slides were
obtained prestained with hematoxylin and eosin from
clinical specimens for the ACCELERATE natural
history registry, scanned, and captured using Aperio
Imagescope. Bars represent 60 (A,E) and 200 mm
(B-D). (A) Regressed GC. (B) FDC prominence in
GC. (C) Blood vessels penetrating GC demonstrate
prominent vascularity. (D) Hyperplastic GC. (E)
Sheet-like plasmacytosis.
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first-line intervention, according to uniform panel consensus. No
high-quality randomized controlled trials exist to substantiate
a level 1 grade recommendation. Recurrences after complete
resection are uncommon, although they have occasionally been
described.12,13,45,53,60,61 Recurrent UCD should be managed
according to the algorithm described in Figure 3 and surgically
excised, if feasible. Follow-up with yearly CT scan imaging studies
for 5 years is therefore recommended. Thereafter, imaging should be
clinically driven based upon suspicion of disease recurrence.50,62
The average size of the lymphadenopathy in UCD is larger than that
in MCD (5.5 vs 3.8 cm).5 These larger lymph nodes can be more
challenging to remove, not only because of their size but also
because of the increased vascularity of UCD, which can cause
severe perioperative bleeding.63-65 Typically, dominant feeding
vessels are present, and several investigators have used pre-
operative embolization to render surgery safer.66-76 We recom-
mend, based on level 2B evidence, that consideration be given to
presurgical embolic devascularization of large UCD lymph nodes
with high risk of bleeding.
Unresectable UCD. Occasionally, a UCD lymph node may
be unresectable because of size or location. This is frequently
encountered in the setting of a mediastinal mass that is close to a main
bronchus or major blood vessel. If surgery is not possible or too
morbid, further treatment is dependent upon the presence of
symptoms resulting from compression of neighboring structures or
systemic inflammation (Figure 3).When possible, expert advice should
be sought to identify the most appropriate therapy for a given patient.
ASYMPTOMATIC UNRESECTABLE UCD. The management of unresect-
able UCD requires a judicial approach. The lymphadenopathy in
patients with UCD can remain stable or grow slowly over time.
There is consensus that a careful watch-and-wait approach can be
adopted in patients with normal laboratory values who are currently
asymptomatic and unlikely to develop future symptoms resulting
from compression of neighboring structures if the mass continues
to grow (level 2B evidence).17,19,77 Selected patients who are
currently asymptomatic but likely to develop symptoms if the mass
continues to grow may need to be treated more aggressively, as if
they have compression-related symptomatic unresectable UCD.
We recommend regular CT scan monitoring at 12-month intervals
as well as annual physical examination and laboratory investigations.
UCD
HV PCMixed
Figure 2. Representative examples of UCD. HV subtype is characterized by the
presence of regressed atretic germinal centers. There is increased vascularity with
hyalinization, prominence of often dysplastic FDCs, and expanded mantle zones in
an onion-skin appearance. There are radially penetrating blood vessels causing a lolli-
pop appearance, multiple germinal centers within the same mantle zone referred to
as twinning or budding, tight aggregates of plasmacytoid dendritic cells, and archi-
tectural disruption with obliterated sinuses. PC subtype exhibits hyperplastic germi-
nal centers and profuse plasmacytosis. Mixed subtype exhibits a combination of
HV and PC features.













Systemic lupus erythematosus, rheumatoid arthritis, Felty’s syndrome
Follicular hyperplasia
Autoimmune lymphoproliferative syndrome
HHV-8–associated MCD or iMCD
EBV, Epstein-Barr virus; NHL, non-Hodgkin lymphoma.
Table 3. Recommended workup of UCD
Assessment category Tests
Imaging CT-PET or CT of neck, chest, abdomen, pelvis
Histopathology HV/mixed/PC
Immunostaining Staining for EBER, LANA-1, and lymphoma or
plasmacytoma markers if suspected
Clonality IgH gene rearrangement, TCR clonality
Virological status HIV serology, HHV-8 qPCR (peripheral blood)
Inflammatory response CBC, renal function, liver function, CRP, ESR,
fibrinogen, immunoglobulins and free light
chains, albumin
Autoimmunity (if suspected) ANA, rheumatoid factor
Monoclonal gammopathy (if suspected) Serum protein electrophoresis with
immunofixation, quantitative
immunoglobulins, and bone marrow if
indicated
Organ function (depending on location
relative to neighboring vital structures)
ECHO, pulmonary function
Workup should include excisional lymph node biopsy for histopathological examination to
confirm features consistent with UCD, establish histopathological subtype, and rule out
Epstein-Barr virus and HHV-8 infection by Epstein-Barr virus–encoded small RNAs (EBER)
and latency-associated nuclear antigen-1 (LANA-1) staining. Blood work is helpful to
exclude HIV infection, autoimmune disorders, and monoclonal gammopathy of
undetermined significance/myeloma as well as measure inflammatory markers and
determine organ function. CT and CT–positron emission tomography (PET) scanning help
to visualize the extent of the disease. Bone marrow examination can exclude a concomitant
plasma cell dyscrasia.
ANA, antinuclear antibody; CBC, complete blood count; ECHO, echocardiogram; IgH,
immunoglobulin H; qPCR, quantitative polymerase chain reaction; TCR, T-cell receptor.
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COMPRESSION-RELATED SYMPTOMATIC UNRESECTABLE UCD. Several
therapeutic options are available if the lymphadenopathy is causing
compressive symptoms but cannot be surgically removed. Partial
resection to debulk the disease without achieving complete removal
can yield good results, but follow-up is required to monitor for
growth, with the frequency of follow-up individualized by the
location, degree of partial resection, and degree of compression
of neighboring structures.15,48,53,62 There have been case reports
in which UCD lymph nodes have been rendered amenable to
surgery through medical therapy with rituximab with or without
steroids. In selected cases, there may be a role for embolization as
adjunctive or alternative therapy.
There have been no systematic studies to evaluate the most effective
approach in these patients (Table 1).13,69,78,79 In a recent series, 21
patients with unresectable UCD received a variety of therapies,
including steroids, chemotherapy, rituximab, and tocilizumab; 7 went
on to have successful surgery.19 Overall, the available evidence and
consensus opinion (level 2B) support the use of rituximab with or
without steroids to reduce the size of compression-related symptom-
atic unresectable UCD. Any persisting lymphadenopathy should be
surgically resected, if feasible. Patients who have unresectable
disease after medical therapy but are rendered asymptomatic can
be observed. Those remaining symptomatic are candidates for
radiotherapy (as described in “Persistent symptomatic unresectable
UCD”).
INFLAMMATION-RELATED SYMPTOMATIC UNRESECTABLE UCD. We con-
sider any symptomatic UCD with inflammatory symptoms (night
sweats, fevers, anorexia, weight loss) and/or laboratory abnormal-
ities (elevated ESR, elevated CRP, or anemia) to be inflammation
related. IL-6 is the well-established driver of symptomatology in
most iMCD patients and rare UCD patients with inflammation-
related symptoms and laboratory abnormalities. Early studies
correlated local production of IL-6 with the systemic manifes-
tations seen in a minority of patients with UCD, because lymph
node excision resulted in relief of symptoms along with a decrease
in serum IL-6 levels.80-82 However, levels of IL-6 and other
inflammatory mediators have not been systematically studied in
a large number of UCD cases. Anti–IL-6 agents siltuximab and
tocilizumab have been thoroughly studied in iMCD and found to



















Figure 3. UCD treatment algorithm. UCD patients should be evaluated for lymph node resectability, with surgery being the preferred method of treatment. 1Consider
presurgical embolization in large vascular UCD lymph nodes to render surgery safer. Follow-up CT scans, physical examination, and laboratory testing can be done at 12-month
intervals. In rare patients who continue to have symptoms after complete lymph node excision, other diagnoses and/or treatments should be considered. 2Watchful observation
is an option in patients with unresectable asymptomatic disease or those with nonsevere compressive symptoms. UCD patients with compression-related symptoms may
benefit from medical treatment (eg, rituximab 6 steroids or anti–IL-6 monoclonal antibody therapy) if inflammatory symptoms (night sweats, fevers, anorexia, weight loss) and/or
laboratory abnormalities (elevated ESR, elevated CRP, or anemia) are present. 3In selected cases, embolization as alternative or adjunctive therapy should be considered. 4
Observation is an option in patients who have been rendered asymptomatic by medical therapy with rituximab/steroids or anti–IL-6 monoclonal antibody therapy. 5Patients who
continue to be symptomatic are candidates for radiotherapy. Alternative options include treatment with immunomodulators/immunosuppressants, such as corticosteroids,
cyclosporine A, and sirolimus.
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appropriate to treat inflammation-related symptomatic unresectable
UCD with siltuximab or tocilizumab, if elevated CRP/ESR or anemia
is present, before considering extensive surgery or radiotherapy
(level 2B).83 However, it should be pointed out that limited data exist
regarding the effectiveness of this approach.19,84 Any persisting
lymphadenopathy should be surgically resected, if feasible. As with
compression-related unresectable UCD, patients who continue to
have unresectable UCD lymphadenopathy after treatment with
anti–IL-6 monoclonal antibody therapy but have become otherwise
asymptomatic can be observed. Patients with ongoing troublesome
symptomatology should be considered for radiotherapy (as de-
scribed in “Persistent symptomatic unresectable UCD”), with
rituximab with or without steroids being an alternative therapeutic
option.
PERSISTENT SYMPTOMATIC UNRESECTABLE UCD. Among unresectable
UCD patients with persistent symptoms and lymphadenopathy
despite therapies directed at the compression- or inflammation-
related symptoms, radiotherapy is an alternative treatment modality
(Table 1). Several early case reports attest to the potential utility of
radiotherapy in UCD.53,85-90 Chronowski et al91 reported on a small
series of 4 patients, 3 of whom achieved complete resolution after
irradiation with doses in the order of 4000 cGy. Chan et al92
identified 17 cases of unresectable UCD in the literature treated
with similar doses of radiotherapy.53,85,87,88,90,91,93-98 Thirteen
achieved disease control, with 7 patients attaining a partial
response and 6 a complete response. At a median follow-up of
20 months, only 1 had died as a result of progressive disease. In
general, radiotherapy was well tolerated, although 1 patient was
reported to have developed PNP.95 However, there is no uniform
consensus among the panel members that therapeutic irradia-
tion is desirable (level 3). Radiotherapy does carry the concern of
late sequelae, which temper enthusiasm for its routine applica-
tion in a benign disorder, especially in younger patients.
An alternative approach to radiotherapy for unresectable UCD
patients with persistent symptoms and lymphadenopathy is
treatment with immunomodulators/immunosuppressants, such
as corticosteroids, cyclosporine A, and sirolimus, which are
more commonly used for iMCD. However, limited data exist on
these treatment approaches (level 3).
Follow-up evaluations. After completion of the initially planned
treatment, patients should be evaluated to determine the disease
response to treatment and should be followed longitudinally for
relapse and complications. One to 3 months after the initial therapy,
the response to treatment should be documented by history,
physical examination, laboratory studies, and imaging.
After excision, patients are followed annually with CT and laboratory
studies, which include complete blood count, lactate dehydroge-
nase, and chemistries with liver and renal function and electro-
lytes, albumin, CRP, and quantitative immunoglobulins. Annual
imaging may be discontinued after 5 years if the patient remains
disease free.
Patients with persisting symptoms after complete surgical
resection. Occasionally, patients continue to report symptoms
after complete surgical extirpation that include persisting fatigue,
lethargy, and other constitutional symptoms. These patients should
be reevaluated to ensure that an alternative diagnosis, such as
iMCD, autoimmune condition, endocrinopathy, depression, chronic
fatigue syndrome, or fibromyalgia, was not missed, which may be
responsible for the symptoms. Appropriate testing (eg, antinuclear
antibody, ESR, CRP, cytokine panel) can help to underpin the
presence of an unrecognized disorder giving rise to inflamma-
tory symptomatology. Absent an alternative etiology to explain
these symptoms, the systemic therapy approaches described in
“Inflammation-related symptomatic unresectable UCD” could be
considered, although additional research is needed to assess their
use in this setting.
An intermediate of CD. There has been recent recognition that
patients can present with a clinical picture that seems to fall
between UCD (1 enlarged lymph node or 1 station of enlarged
lymph nodes) and iMCD (.1 station of enlarged lymph nodes, and
often .5 stations, with cytokine-driven systemic inflammation).
Specifically, these patients often have enlarged lymph nodes in 2 to
3 adjacent lymph node stations, but they lack sufficient clinical and
laboratory abnormalities to meet the iMCD diagnostic criteria.
These cases have been tentatively described as regional or
oligocentric CD. More research is needed, but we felt it was
important to recognize this entity in this report, because it may
require different treatments than iMCD. In fact, the clinical and
pathological features of regional CD resemble those of UCD
closely.83 Based on the current limited experiences of the panel
and lack of available peer-reviewed evidence, we believe that
surgical removal or debulking should be considered (level 2B)
over extensive morbid surgeries and systemic therapies, particularly
cytotoxic chemotherapies, if possible.19,83 This more conservative
approach avoids long-term adverse effects and is prudent given the
often indolent clinical course. However, regional CD with in-
flammatory symptoms may benefit from treatment according to the
iMCD treatment algorithm, particularly when exhibiting the PC
histopathological subtype.
Disorders associated with UCD. A number of disorders can
present in conjunction with UCD or arise after UCD. These include
PNP, Hodgkin disease (HD) or NHL, and FDCS. A survey of the
French registry of CD showed that 18% of UCD patients had
a complicating disorder.19
PNP. UCD associated with PNP deserves special mention, because
it is life threatening and often accompanied by progressive BO.99
The frequency of this associated disorder seems to be particularly
high in the Asian population.100 PNP and BO typically occur in the
setting of the HV histopathologic subtype of UCD, sometimes
associated with stroma-rich features.41 Complete surgical removal
of UCD should be performed in patients with UCD and PNP; this
has been reported to often halt or reverse the PNP.100,101 BO has
a high fatality rate, despite treatment with a variety of agents alone
or in combination, including corticosteroids, rituximab, cyclosporine
A, and cyclophosphamide.25,99,102,103 The expert panel agrees that
therapy with an anti–IL-6 monoclonal antibody has limited anecdotal
efficacy in PNP.
FDCS. FDCS is a rare form of sarcoma arising from FDCs that can
cooccur with the HV histopathologic subtype of UCD.104-106 In
a large single-institution series of 66 patients with FDCS, 6 were
found to have UCD, and in 2, the diagnosis of UCD preceded that of
FDCS. The preferred therapy for localized FDCS is resection, and
additional consolidative radiotherapy should be considered for local
control.107,108 Chemotherapy is recommended for metastatic FDCS.
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LYMPHOMA. Distinguishing lymphoma from UCD can be challeng-
ing. HD has been reported in patients with UCD; however, the UCD
plasmacytic-like histopathological changes may simply represent
reactive changes secondary to the HD. UCD and HD are most
frequently observed in the same lymph node, emphasizing the need
for complete surgical excision.109 A few cases of UCD preceding
HD have been described.109-113 A review of 23 cases reported in
the literature revealed that 21 cases were described as having PC
histopathology, and 2 had mixed histopathology.109 A majority of
the HD patients had B symptoms. PC UCD–like lymph node
changes may be due to IL-6 and other cytokines produced by
Reed-Sternberg cells. Occasionally, CD-like changes are found
in a distant lymph node, which can delay the diagnosis of HD.
In contrast, NHL is more often associated with UCD with HV
histopathology. In a series reporting NHL and UCD cooccur-
rence, NHL was less commonly present in the same lymph node
as UCD (37%) and was instead found in different anatomical
areas (72%).114 Both B- and T-cell lymphomas have been
described to cooccur with UCD. FL with features reminiscent of
HV UCD may be present in some patients as an unusual
morphological variant of FL that may create diagnostic difficul-
ties.114 Taken together, the precise relationship between UCD
and both HD and NHL remains unclear. Regardless, the risk of
having an HD or NHL diagnosis concurrently or subsequent to
a UCD diagnosis seems to be low.
Therapy for UCD and NHL or HD should primarily be dictated
by the lymphoma and may include excision, radiotherapy, and
chemotherapy.
Discussion
The present consensus guidelines for UCD complement the
previous recommendations for iMCD. It is important to accurately
diagnose UCD by ruling out conditions with overlapping histopa-
thology, distinguishing UCD from iMCD, and evaluating the
resectability and symptomatology associated with each case.
We recommend complete surgical resection as the preferred
intervention for UCD whenever possible. Recurrence of UCD after
complete surgical removal is rare. Occasionally, the distinction
between UCD and iMCD is not clearly delineated, with some
patients exhibiting more regional lymphadenopathy. These patients
typically have a more indolent clinical course and may benefit from
UCD-directed rather than iMCD-directed treatment. The most
challenging scenario in UCD is that of unresectable UCD. These
cases require a judicial approach, with some benefiting from
medical cytoreduction followed by surgery and others better
served with surgical debulking followed by careful observation.
Unresectable asymptomatic UCD patients may also be man-
aged with surveillance alone. In patients with unresectable UCD
and inflammation-related symptomatology, anti–IL-6 therapy
may be effective. Radiotherapy is an acceptable alternative for
unresectable UCD but should probably be avoided in younger
patients when possible. Further research is urgently needed into
the most effective approaches for unresectable UCD, regional
CD, and anti–IL-6 refractory iMCD patients. The CDCN interna-
tional ACCELERATE natural history registry32 collects data re-
garding the clinical characteristics, therapies, and outcomes of all
forms of CD to advance knowledge regarding this complex and
heterogeneous disorder. The University of Pennsylvania and CDCN
are also able to consent, coordinate, and receive excess lymph
node tissue from clinically warranted lymph node biopsies for
research purposes.115 The ACCELERATE registry and lymph node
biospecimens support ongoing clinical and translational research
efforts, with the twin goals of strengthening the evidence base to
help physicians in selecting optimal treatment approaches and
identifying new rational therapeutic modalities, particularly for
patients with unresectable UCD.
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